ArticleiScience2025
Added value of serum proteins to clinical and ultrasound information in predicting the risk of malignancy in ovarian tumors.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Assessment of Different Neoplasias in the Adnexa (ADNEX) is the best-performing model to estimate the risk of malignancy in ovarian tumors. We assessed the incremental value of serum proteins over ADNEX predictors in an exploratory multicenter study. In a cohort of 932 patients with an adnexal mass scheduled for surgery, 33 serum proteins were preoperatively quantified using multiplex high-throughput and electrochemiluminescence immunoassays. Using multivariable logistic regression, ADNEX predictors alone had an area under the receiver operating characteristic curve (AUC) of 0.91 (95% confidence interval, 0.89-0.93) to discriminate benign from malignant tumors. This AUC increased most after adding HE4 (+0.03) or CA125 (+0.02). CA72.4 increased AUCs to discriminate secondary metastatic tumors from benign (+0.03), borderline (+0.03), and stage I tumors (+0.03). CA15.3 increased AUCs to discriminate borderline tumors from stage I (+0.01) and stage II-IV tumors (+0.03). While CA125 and HE4 had the highest added value over ADNEX predictors, CA72.4 and CA15.3 may improve discrimination between malignant subtypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.